化工社化工社化学情報印刷レポート · 研究参考用

HCID 62878作成日：2026年10月27日

Paroxetine Hydrochloride

D6-Paroxetine HCl (Mixture of Enantiomers) · (3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine HCl

https://huagongshe.com/ja/chemical/62878

識別子と物理属性

CAS No.	130855-16-2
分子式	C19H21ClFNO3
平均分子量	365.8 g/mol
単同位体質量	365.11939943 g/mol
SMILES	Cl.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
InChIKey	GELRVIPPMNMYGS-RVXRQPKJSA-N
PubChem CID	62878
ChEMBL	CHEMBL1708
ChEBI	CHEBI:7944
EC No.	616-601-1
DTXSID	DTXSID50228914

化学・物理的性質

極性表面積	39.7
水素結合供与体数	2
水素結合受容体数	5
回転可能結合数	4
重原子数	25
形式電荷	0
複雑度	402
Human Drugs	FDA approved drugs -> Active ingredient
Collision Cross Section	181.1 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]
融点	116.4-118.4 °C

安全性と法規制

GHS 分類	DangerH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P304+P340, P305+P354+P338, P317, P319, P330, P391, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 58 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
規制情報	Paroxetine hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Hazard Classes and Categories	Acute Tox. 4 (100%)
Treatment	Treatment should consist of those general measures employed in the management of overdosage with any drugs effective in the treatment of major depressive disorder. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. Activated charcoal should be administered. Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for paroxetine are known. (L1712)
暴露経路	Paroxetine hydrochloride is slowly, but completely absorbed following oral administration. Paroxetine mesylate salt is also completely absorbed after oral dosing. The oral bioavailability appears to be low due to extensive first-pass metabolism. Paroxetine hydrochloride oral tablets and suspension are reportedly bioequivalent. Absorption of either salt form is not substantially affected by food. Peak concentrations of Brisbelle (mesylate salt) were reached at 6 hours (3 to 8 hours range). Steady state Cmax was 13.10 ng/mL. The steady state AUC (0-last) was 237 hr*ng/mL. Paroxetine mesylate generally follows non-linear pharmacokinetics because CYP2D6, the enzyme that is part responisible for paroxetine metabolism, is readily saturable.
毒性の概要	Paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS

CAS No.

130855-16-2

分子式

C19H21ClFNO3

平均分子量

365.8 g/mol

単同位体質量

365.11939943 g/mol

SMILES

Cl.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1

InChIKey

GELRVIPPMNMYGS-RVXRQPKJSA-N

PubChem CID

62878

ChEMBL

CHEMBL1708

ChEBI

CHEBI:7944

EC No.

616-601-1

DTXSID

DTXSID50228914

化学・物理的性質

極性表面積

39.7

水素結合供与体数

水素結合受容体数

回転可能結合数

重原子数

形式電荷

複雑度

402

Human Drugs

FDA approved drugs -> Active ingredient

Collision Cross Section

181.1 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]

融点

116.4-118.4 °C

安全性と法規制

GHS 分類

DangerH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P304+P340, P305+P354+P338, P317, P319, P330, P391, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 58 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

規制情報

Paroxetine hydrochloride: Does not have an individual approval but may be used under an appropriate group standard

Hazard Classes and Categories

Acute Tox. 4 (100%)

Treatment

Treatment should consist of those general measures employed in the management of overdosage with any drugs effective in the treatment of major depressive disorder. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. Activated charcoal should be administered. Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for paroxetine are known. (L1712)

暴露経路

Paroxetine hydrochloride is slowly, but completely absorbed following oral administration. Paroxetine mesylate salt is also completely absorbed after oral dosing. The oral bioavailability appears to be low due to extensive first-pass metabolism. Paroxetine hydrochloride oral tablets and suspension are reportedly bioequivalent. Absorption of either salt form is not substantially affected by food. Peak concentrations of Brisbelle (mesylate salt) were reached at 6 hours (3 to 8 hours range). Steady state Cmax was 13.10 ng/mL. The steady state AUC (0-last) was 237 hr*ng/mL. Paroxetine mesylate generally follows non-linear pharmacokinetics because CYP2D6, the enzyme that is part responisible for paroxetine metabolism, is readily saturable.

毒性の概要

Paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS